Close Menu

This article has been corrected to note that the FDA is expected to issue a decision on Pfizer's sNDA by January 2021, not 2020.

NEW YORK – Pfizer on Wednesday said that the US Food and Drug Administration has accepted its supplemental new drug application for crizotinib (Xalkori) for treating pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) characterized by ALK rearrangements.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.